Invion stock analysis
Want to see AU:IVX full AI Analyst Report?
Invion (IVX) Share Price & Analysis
IVX Stock Chart & Stats
- Day’s Range
- AUD 0.04 - AUD 0.04
- 52-Week Range
- AUD 0.03 - AUD 0.11
- Previous Close
- AUD 0.03
- Volume
- N/A
- Average Volume (3M)
- 63.07K
- Market Cap
- AUD 3.65M
- Enterprise Value
- AUD 4.42M
- Total Cash (Recent Filing)
- AUD 592.31K
- Total Debt (Recent Filing)
- AUD 1.55M
- Price to Earnings (P/E)
- ―
- Beta
- -0.42
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Therapy Platform
A proprietary Photosoft™ platform gives Invion a defined technological base for developing photodynamic cancer treatments. Its light-activated approach is intended to selectively destroy cancer cells and may also stimulate anti-tumour immune responses, creating potential differentiation if clinical development succeeds.
Focused Oncology Pipeline
The company is focused on a substantial oncology opportunity rather than pursuing an unfocused portfolio. Initial work in breast and ovarian cancer, combined with nanoparticle delivery formulations, provides identifiable development programs around which future clinical validation and partnerships could be built.
Moderate Reported Leverage
Reported debt is moderate relative to the latest equity balance, so leverage is not currently the central financial constraint. This gives Invion more balance-sheet flexibility than a heavily indebted development company, although its ability to use that flexibility remains limited by losses and cash consumption.
Bears Say
Persistent Unprofitability
Recurring operating and net losses show that Invion has not yet converted its research activities into a profitable operating model. Continued losses can consume capital, restrict investment in clinical development, and make future financial performance dependent on achieving successful commercialization or securing additional funding.
Unstable And Weak Revenue Base
The sharp collapse in revenue and only limited recovery indicate an unstable commercial base rather than a durable growth trajectory. Such a low and volatile revenue run-rate provides little evidence of recurring market demand, leaving the company exposed to prolonged development timelines before meaningful operating scale emerges.
Ongoing Cash Burn And Reduced Resilience
Negative operating cash flow and mostly negative free cash flow indicate that Invion remains reliant on external capital or balance-sheet resources to fund operations. The accompanying erosion of equity materially reduces financial resilience and may constrain the duration and scale of ongoing research and development.
Invion News
IVX FAQ
What was Invion’s price range in the past 12 months?
What is Invion’s market cap?
When is Invion’s upcoming earnings report date?
How were Invion’s earnings last quarter?
Is Invion overvalued?
Does Invion pay dividends?
What is Invion’s EPS estimate?
How many shares outstanding does Invion have?
What happened to Invion’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Invion?
What is the TipRanks Smart Score and how is it calculated?
Invion Stock Smart Score
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Thian Chew
- Employees
- 8
- Website
- www.inviongroup.com
- Address
- 385 Bourke Street, Melbourne, VIC, 3000, AU
Invion (IVX) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 2 | 14 |
| Technical Analysis | 5 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |









